{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"82.87","value":"-39.31"},{"groupId":"OG001","spread":"87.20","value":"-25.15"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"Bone markers Dickkopf homolog 1 (DKK-1) was measured on serum samples.","dispersionType":"Standard Deviation","groups":[{"description":"bortezomib (Velcade) 1.6 mg/m² bolus injection on Days 1, 8, 15 and 22 every 5 weeks for 4 cycles","id":"OG000","title":"Bortezomib"},{"description":"no treatment, observation only","id":"OG001","title":"Non-treated Control"}],"paramType":"MEAN","populationDescription":"FAS was used for analysis. \"N\" (number of subjects analyzed) signifies the subjects evaluable this measure and n=number pf participants analysed for this outcome measure at specific time point. Missing data was imputed by last observation carried forward (LOCF) method.","reportingStatus":"POSTED","timeFrame":"Baseline up to end of study (approximately 4 years 7 months)","title":"Change From Baseline in Biochemical Bone Markers: Dickkopf Homolog 1 (DKK-1)","type":"SECONDARY","unitOfMeasure":"Picomole per liter"}